David Young, President Research & Development at Processa Pharmaceuticals, Inc. (PCSA), bought 1,706 shares at $2.69 ($5K) on 2026-04-30, disclosed to the SEC on 2026-05-01.
Open-market purchase of $5k PCSA by President Research & Development. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| PCSA | BUY | 2026-06-01 | $5K | — | Filing → |
| PCSA | BUY | 2026-05-19 | $5K | — | Filing → |
| PCSA | BUY | 2026-04-17 | $5K | — | Filing → |